首页 | 本学科首页   官方微博 | 高级检索  
检索        


Patients with resectable pancreatic adenocarcinoma: A 15-years single tertiary cancer center study of laparotomy findings,treatments and outcomes
Authors:Marine Gilabert  Olivier Turrini  Jacques Ewald  Laurence Moureau-Zabotto  Flora Poizat  Jean-Luc Raoul  Jean-Robert Delpero
Institution:1. Department of Medical Oncology, Paoli-Calmettes Institute, 13232, Marseille Cedex 9, France;2. Department of Digestive Surgery, Paoli-Calmettes Institute, 13232, Marseille Cedex 9, France;3. Department of Radiotherapy, Paoli-Calmettes Institute, 13232, Marseille Cedex 9, France;4. Department of Pathology, Paoli-Calmettes Institute, 13232, Marseille Cedex 9, France
Abstract:

Background

To describe, in patients with resectable pancreatic ductal adenocarcinoma (PDAC), the laparotomy findings, treatments and outcomes before (period 1) and after 2010 (period 2).

Methods

From 2000 to 2015, patients newly diagnosed with resectable PDAC at Paoli-Calmettes Institute, France, were evaluated. Survival was examined using the Kaplan-Meier method, and statistical comparisons were conducted using log rank tests.

Results

Among 1175 patients diagnosed with pancreatic mass, 164 underwent laparotomy with an intention of pancreatic resection. Some of them did not undergo pancreatic resection due to peroperative discovery of advanced disease. For those who were finally resected (n?=?119), there were fewer pancreaticoduodenectomies (p?=?0.045), shorter operation times (p?<?0.01), lower mortality rates (p?=?0.02), more advanced-stage tumors (T3), more frequent perineural invasion and R1 resection in period 2. This group had a trend of better outcomes after 2010 (51 months vs. 36 months (p?=?0.065)).

Conclusion

Improvement in surgical procedures and postoperative management led to prolonged survival of those who underwent surgery for resectable pancreatic cancer since 2010, despite a higher frequency of advanced tumors at the diagnosis in our institution.
Keywords:Pancreatic adenocarcinoma  Resectable tumor  Laparotomy  Survival  PDAC  Pancreatic ductal adenocarcinoma  OS  overall survival  PFS  progression free survival  DFS  disease free survival  SMV  Superior mesenteric vein  SMA  Superior mesenteric artery  PV  Portal Vein  ESPAC  European Study Group for Pancreatic Cancer  EORTC  European Organization for Research and Treatment of Cancer
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号